Trials / Completed
CompletedNCT00889538
Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems
Double-Blind, Placebo-Controlled, Crossover Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- University of Louisville · Academic / Other
- Sex
- All
- Age
- 5 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of glutathione alone or glutathione, vitamin C and NAC treatment in children with autism who also have severe behavior problems. The investigators hypothesis is that children with autism will show improvement in both learning capabilities and behavior with either glutathione, or glutathione, vitamin C and NAC therapy.
Detailed description
This is a prospective, single center, double-blind, randomized pilot study in children and adolescents with autism and severe behavior disorders. All subjects will undergo initial screening procedures to determine eligibility. They will then be randomized to either 8 weeks of placebo or 8 weeks of glutathione or glutathione, vitamin C and N-acetylcysteine. They will receive intravenous treatment weekly and will have ongoing behavioral studies during this period. Following 8 weeks of therapy, they will have a week without treatment then will cross-over to the alternate therapy for weekly intravenous infusions and behavioral testing. In addition to baseline hematology and chemistries, baseline oxidized and reduced glutathione will be measured. These parameters will be repeated at the end of each 8 week course of therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | placebo | 50 mL of 1/2 normal saline IV |
| DRUG | glutathione | glutathione 600 mg IV |
| DRUG | glutathione, vit C and NAC | Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2009-04-29
- Last updated
- 2016-12-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00889538. Inclusion in this directory is not an endorsement.